Deferoxamine enhances neovascularization and recovery of ischemic skeletal muscle in an experimental sheep model

Annals of Thoracic Surgery

Volumn 75, Issue 1, 2003, Pages 184-189

  Chekanov, Valeri S ^a,b   Nikolaychik, Victor ^a,b   Maternowski, Michelle A ^a,b   Mehran, Roxana ^a,b   Leon, Martin B ^a,b   Adamian, Milena ^a,b   Moses, Jeffrey ^a,b   Dangas, George ^a,b   Kipshidze, Nicholas ^a,b,c   Akhtar, Masood ^a,b  

^a Milwaukee Heart Institute   (United States)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^c Lenox Hill Heart/Vascular Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; DEFEROXAMINE; FIBRIN GLUE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; CAPILLARY DENSITY; CONTROLLED STUDY; DRUG EFFICACY; INJECTION; LATISSIMUS DORSI MUSCLE; MOBILIZATION; MUSCLE ISCHEMIA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; SHEEP; SHOCK; SKELETAL MUSCLE;

ANIMALS; DEFEROXAMINE; FIBRIN TISSUE ADHESIVE; IRON CHELATING AGENTS; ISCHEMIA; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; SHEEP;

EID: 0037232582     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(02)04122-X     Document Type: Article

References (24)

1. Varami Y, Dame DM, Diaz M, et al. Deferoxamine interferes with adhesive functions of activated human neutrophils. Shock 1996;6:395-402.
2. Beerepoot LV, Shima DT, Kuroki M, et al. Up-regulation of vascular endothelial growth factor production by iron chelator. Cancer Res 1996;56(16):3747-51.
3. Fasol R, Schumacher B, Schlaudraff K, et al. Experimental use of a modified fibrin glue to induce site-directed angiogenesis from the aorta to the heart. J Thorac Cardiovasc Surg 1994;107:1432-9.
4. Dvorak HF, Harvey VS, Estrella P, et al. Fibrin containing gels induce angiogenesis: implication for tumor stroma generation and wound healing. Lab Invest 1987;57(6):673-82.
5. Chekanov V, Nikolaychik V, Tchekanov G, et al. The use of biological glue for better adhesions between the skeletal muscle flap and the myocardium and for increasing capillary ingrowth. J Thorac Cardiovasc Surg 1996;111:678-80.
6. Boyce St T, Holder IA, Supp AP, et al. Delivery and activity of antimicrobial drugs released from human fibrin sealant. J Burn Care Rehabil 1994;15:251-5.
7. Kabuto M, Kubota T, Kobayashi H, et al. Experimental study of intraoperative local chemotherapy with fibrin glue containing nitrosourea for malignant gliomas. Surg Neurol 1995;44(2):151-7.
8. Lasa C Jr, Hollinger J, Drohan W, et al. Delivery of demineralized bone powder by fibrin sealant. Plast Reconstr Surg 1995;96(6):1409-18.
9. Kang SS, Gosselin C, Ren D, Greisler HP. Selective stimulation of endothelial cell proliferation with inhibition of smooth muscle cell proliferation by fibroblast growth factor-1 plus heparin delivered from fibrin glue suspensions. Surgery 1995;118(2):280-7.
10. Chekanov VS, Maternowski MA, Eisenstein R, et al. Angiogenesis in the latissimus dorsi muscle using different regimens of electrical stimulation and pharmaceutical support. ASAIO J 2000;46(3):305-12.
11. Nikolaychik VV, Chekanov VS, Hernandez I, et al. Biodesign of a skeletal muscle flap as a model for cardiac assistance. Art Organs 2000;24(2):137-47.
12. Chekanov VS, Nikolaychik VV. Iron contributes to endothelial dysfunction in acute ischemic syndrome. Circulation 2002;105(4):E35-5.
13. Bauer C, Marzi I, Larsen R. Deferoxamine-conjugated hydroxyethyl stack reduces reperfusion injury to the liver following hemorrhagic shock. Anesthesiologist 1997;46(1):53-6.
14. Moch D, Schroppel B, Schoenberg M, et al. Protective effects of hydroxyethyl starch-deferoxamine in early sepsis. Shock 1995;4(6):425-432.
15. Katoh S, Toyama J, Kodama I, et al. Protective action of iron-chelating agents (catechol, mimosine, deferoxamine, and kojic acid) against ischemia-reperfusion injury of isolated neonatal rabbit hearts. Eur Surg Res 1992;24(6):349-55.
16. Morris SF, Pang DCY, Lofehy Lofchi NM, et al. Deferoxamine attenuates ischemia-induced reperfusion injury in the skin and muscle of myocutaneous flaps in pigs. Plast Reconstr Surg 1993;92(1):120-32.
17. Fantini GA, Yoshioka T. Deferoxamine prevents lipid peroxidation and attenuates reoxygenation injury in postischemic skeletal muscle. Am J Physiol 1993;264(6 Pt 2):1953-9.
18. Hickley MY, Hickey MJ, Knight KR, et al. Influence of postischemic administration of oxyradical antagonists on ischemic injury to rabbit skeletal muscle. Microsurgery 1996;17(9):517-23.
19. Patterson E. Coronary vascular injury following transient coronary artery occlusions: prevention by pretreatment with deferoxamine, dimethylthiourea and N-2 mercaptoproprionyl glycine. J Pharmacol Exp Ther 1993;266(3):1528-35.
20. Drosse G, Lazou A, Panagopoulos P, et al. Deferoxamine cardioplegia reduces superoxide radical production in human myocardium. Ann Thorac Surg 1995;59:169-72.
21. Morita K, Ihnken K, Buckberg GD, et al. Studies of hypoxemic/reoxygenation injury: deferoxamine. J Thorac Cardiovasc Surg 1995;110(4 Pt 2):1190-9.
22. Spencer KT, Lindower PD, Buettner GR, Kerber RE. Transition metal chelators reduce directly measured myocardial free radical production during reperfusion. J Cardiovas Pharmacol 1998;32(3):343-8.
23. Chekanov VS, Karakozov PE, Reider M, Zander G. Age related skeletal muscle response to electrical stimulation. ASAIO J 2000;46:474-81.
24. Chekanov VS. Multistep approach to electrical stimulation after cardiomyoplasty. J Card Surg 2000;15:199-208.